FDA panel to rate cooling catheter
This article was originally published in The Gray Sheet
Executive Summary
Circulatory System Devices Panel convenes March 17 in Gaithersburg, Md. to review a 510(k) submission for a device applying mild hypothermia to treat patients rendered unconscious by cardiac arrest. Alsius' CoolGard system, which uses a proprietary catheter to fill two MicroTherm cooling balloons in the superior vena cava, currently lacks the indication under review. [Editor's note: To order a webcast or DVD of the panel meeting, visit "The Gray Sheet" affiliate 1www.FDAAdvisoryCommittee.com.] Radiant Medical markets Reprieve, a second-gen version of the SetPoint endovascular temperature management system, cleared in 2002 for "cardiac surgery patients to achieve and/or maintain normothermia during surgery and recovery/intensive care." Panelists agreed last September that safety studies are needed to assess hypothermia as therapy for comatose patients after cardiac arrest (2"The Gray Sheet" Sept. 27, 2004, p. 5)...
You may also be interested in...
FDA Panel Urges Safety Studies Of Cooling-Catheters For Cardiac Arrest Group
Clinical trials of endovascular cooling catheters should focus primarily on safety, since the devices are at least as effective as surface cooling methods to achieve hypothermia-induced resuscitation, FDA panelists agreed Sept. 21
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.